Ribavirin and Common peroneal nerve dysfunction - a phase IV clinical study of FDA data

Summary:

Common peroneal nerve dysfunction is reported as a side effect among people who take Ribavirin (ribavirin), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Aspirin, and have Pain.

The phase IV clinical study analyzes which people have Common peroneal nerve dysfunction when taking Ribavirin. It is created by eHealthMe based on reports of 78,378 people who have side effects when taking Ribavirin from the FDA, and is updated regularly.

What is Ribavirin?

Ribavirin has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 78,532 Ribavirin users. Check the latest studies of Ribavirin.

What is Common peroneal nerve dysfunction?

Common peroneal nerve dysfunction (dysfunction of nerve controlling movement and sensation to the lower leg, foot and toes) is found to be associated with 651 drugs and 1,130 conditions by eHealthMe. Check the latest studies of Common peroneal nerve dysfunction.

On Aug, 09, 2026

78,378 people reported to have side effects when taking Ribavirin.
Among them, 25 people (0.03%) have Common peroneal nerve dysfunction.

Could Ribavirin cause Common peroneal nerve dysfunction?

Among these 25 people:

How long have people been on Ribavirin when they have Common peroneal nerve dysfunction? *

What is the gender of people who have Common peroneal nerve dysfunction when taking Ribavirin? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Common peroneal nerve dysfunction when taking Ribavirin? *

What are other drugs people take besides Ribavirin? *

What are other side effects people have besides Common peroneal nerve dysfunction? *

Fall: 10 people, 40.00%
Weakness: 8 people, 32.00%
Kidney Stones: 6 people, 24.00%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 6 people, 24.00%
Rashes (redness): 6 people, 24.00%
Drug Hypersensitivity: 5 people, 20.00%
Oral Disorder (mouth disease): 5 people, 20.00%
Staphylococcus Test Positive: 5 people, 20.00%
Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function): 5 people, 20.00%
Scab (a hard coating on the skin formed during the wound healing): 5 people, 20.00%

What are the existing conditions these people have? *

Pain: 2 people, 8.00%
Vitamin D Decreased: 1 person, 4.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.00%
Angiopathy (generic term for a disease of the blood vessels): 1 person, 4.00%
Aortic Calcification (aortic calcification sign of heart valve disease): 1 person, 4.00%
Ards (Acute Respiratory Distress Syndrome) (sudden failure of the respiratory (breathing) system): 1 person, 4.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 4.00%
Bowel Movement Irregularity: 1 person, 4.00%
Depression: 1 person, 4.00%
Electrolyte Imbalance: 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ribavirin and have Common peroneal nerve dysfunction?

- Check whether Common peroneal nerve dysfunction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ribavirin:

Ribavirin (78,532 reports)

Browse all side effects of Ribavirin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Common peroneal nerve dysfunction:

Common peroneal nerve dysfunction (651 drugs)

Browse all the conditions that are associated with Common peroneal nerve dysfunction:

Common peroneal nerve dysfunction (1,130 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Ribavirin) and Ribavirin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.